Vivistim
Commercial- Indications
- Chronic ischemic stroke, Upper extremity motor deficits
Company intelligence / Profile preview
The Vivistim® Paired VNS™ System has demonstrated significant and clinically meaningful improvements in upper limb function for chronic ischemic stroke survivors. Published data show that after a six-week protocol of in-clinic occupational or physical therapy combined with the device, patients achieved two to three times more improvement than with high-intensity therapy alone. One-year follow-up data confirm durable benefits as measured by standard motor function assessments such as Fugl-Meyer Assessment – Upper Extremity and Wolf Motor Function Test. Real-world adoption includes programs at major US stroke centers.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MicroTransponder.